Ignite Creation Date:
2024-05-06 @ 3:17 AM
Last Modification Date:
2024-10-26 @ 11:31 AM
Study NCT ID:
NCT02259114
Status:
COMPLETED
Last Update Posted:
2021-01-26
First Post:
2014-10-03
Brief Title:
A Dose-Finding Study of Birabresib MK-8628 a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal BET Proteins in Adults With Selected Advanced Solid Tumors MK-8628-003
Sponsor:
Organization:
Oncoethix GmbH a subsidiary of Merck Co Inc Rahway New Jersey USA
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
47
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: